Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 1.81B |
| Revenue (ttm) | 8.82M |
| Net Income (ttm) | -149.93M |
| Shares Out | 39.91M |
| EPS (ttm) | -3.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,143,591 |
| Open | 48.36 |
| Previous Close | 48.36 |
| Day's Range | 44.67 - 48.82 |
| 52-Week Range | 19.38 - 48.82 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 85.05 (+87.7%) |
| Earnings Date | Aug 9, 2022 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbe... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is 85.05, which is an increase of 87.67% from the latest price.
News
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
Why Axsome Therapeutics Topped the Market Today
The company records nearly $9 million in quarterly sales from its recently acquired drug.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time
3 Beaten-Down Stocks That Could Soar in the Second Half of 2022
Each of these stocks is ready for a rebound.
What's Winning in 2022? 3 Stocks That Are Doing Fine
Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,00...
Los Angeles, California--(Newsfile Corp. - July 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, I...
AXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Beha...
NEW YORK , July 12, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) alleging that the...
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in A...
NEW YORK , July 11, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and certain of it...
AXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcom...
New York, New York--(Newsfile Corp. - July 11, 2022) - Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsu...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome The...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 12, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors w...
AXSM FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors With Lo...
New York, New York--(Newsfile Corp. - July 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between De...
DEADLINE TOMORROW ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,00...
Los Angeles, California--(Newsfile Corp. - July 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, I...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, ...
NEW YORK , July 11, 2022 /PRNewswire/ -- Attention Axsome Therapeutics, Inc. ("Axsome") (NASDAQ: AXSM) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on...
TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,00...
Los Angeles, California--(Newsfile Corp. - July 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, In...
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022
NEW YORK , July 8, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM). To rece...
TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,...
Los Angeles, California--(Newsfile Corp. - July 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Axsome Therapeutics, In...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of a Class Action Lawsuit an...
NEW YORK , July 6, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Axsome Therapeutics, Inc.. Shareholders who purchased shares of AXSM during the class period lis...
AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit
Shareholders with $500,000 losses or more are encouraged to contact the firm. LOS ANGELES , July 5, 2022 /PRNewswire/ -- The Law Offices of Frank R.
3 Growth Stocks That Could Make You Richer in the Second Half of 2022
These stocks appear to have good chances of delivering solid gains by year-end.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, In...
New York, New York--(Newsfile Corp. - July 3, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) and ...
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Befo...
NEW YORK , June 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Axsome Therapeutics, Inc. (NASDAQ: AXSM) between December 30, 20...